Company / SG&A Expense
Perspective Therapeutics, Inc. SG&A Expense History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$5.6M
FY2022
5-year range
$3.8M / $5.6M
FY2018-FY2022
Trend
+33.5%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 5 consecutive years, from $2M in FY2017 to $6M in FY2022.
Based on SEC 10-K filings.
$6M in FY2022 with a 5-year CAGR of +18.3%.
Increased from $4M to $6M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +12.4%
- 5-Year CAGR
- +18.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Perspective Therapeutics, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +18.3%, indicating consistent growth.
- In FY2022, sg&a expense increased 33.5% year-over-year.
- Lowest sg&a expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $5.6M | +33.5% |
| FY2021 | $4.2M | +0.2% |
| FY2020 | $4.2M | +6.3% |
| FY2019 | $3.9M | +3.5% |
| FY2018 | $3.8M | +57.7% |
| FY2017 | $2.4M | -3.5% |
| FY2016 | $2.5M | +8.5% |
| FY2015 | $2.3M | +0.0% |
| FY2014 | $2.3M | -2.6% |
| FY2013 | $2.4M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026